RecruitingEarly Phase 1NCT05152732
Safety and Tolerability of VGB-R04 in Patients With Haemophilia B
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment
3 participants
Start Date
Dec 28, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
An Open-Label, Non-Randomized, uncontrolled, single-dose pilot study of VGB-R04 in subjects with Hemophilia B.
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 75 Years
Inclusion Criteria13
- Male ≥18 years and ≤75years of age;
- Confirmed diagnosis of hemophilia B (baseline FIX activity ≤ 2% of normal or documented history of FIX activity ≤2%);
- At least 100 days exposure history to FIX;
- Currently receiving FIX Prophylaxis therapy or on-demand treatment to prevent bleeding;
- Have acceptable laboratory values:
- Hemoglobin ≥110 g/L;
- Platelets ≥100×10'9 cells/L;
- AST, ALT, alkaline phosphatase ≤2×upper limit of normal (ULN) at the testing laboratory;
- Bilirubin ≤3× ULN ;
- Creatinine ≤1.5× ULN.
- No measurable factor IX inhibitor as assessed by the central laboratory and have no prior history of inhibitors to factor IX protein;
- Agree to use reliable barrier contraception until 3 consecutive samples are negative for vector sequences;
- Able to provide informed consent and comply with the requirements of the study.
Exclusion Criteria17
- Have significant underlying liver disease within the past 6 months prior to or at Screening, including but not limited to:
- Preexisting diagnosis of portal hypertension;
- Splenomegaly;
- Encephalopathy;
- Reduction of serum albumin;
- Evidence of significant liver fibrosis;
- Have anti-VGB-R04 neutralizing antibody titers ≥1:5;
- Evidence of severe infection disease, i.e., human immunodeficiency virus (HIV) infection, syphilis, tuberculosis, etc.;
- Evidence of active hepatitis B virus infection (HBV-DNA >103 IU/ml) or hepatitis C virus infection (HCV antigen and HCV-RNA positive);
- Evidence of malignant tumours or those with a previous history of malignant tumours;
- Have a history of chronic infection or other chronic diseases that the Investigator considers to constitute an unacceptable risk;
- Any immunodeficiency;
- Participated in a gene transfer trial within the last 52 weeks or in a clinical trial with an investigational drug within the last 4 weeks;
- Have used glucocorticoids, immunosuppressive drugs, or antipsychotics within the last 3 months;
- Previous history of hypersensitivity or allergic reaction to any FIX products or any immunoglobulin;
- Unable or unwilling to comply with the schedule of visits and study assessments described in the clinical protocol;
- Any concurrent clinically significant major disease or any other condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
GENETICVGB-R04
A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05152732
Related Trials
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT0556871917 locations
Lentiviral FIX Gene Therapy
NCT039612431 location
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
NCT061474141 location
ATHNdataset Registry
NCT068205151 location
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
NCT0708090510 locations